Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Squamous Non-small Cell Lung Cancer × tremelimumab × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 22 Lung Neoplasms 10 Small Cell Lung Carcinoma 9 Mesothelioma, Malignant 5 Squamous Cell Carcinoma of Head and Neck 4 Melanoma 4 Mesothelioma 3 Neoplasm Metastasis 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1 Peritoneal Neoplasms 1 Part A and B: Advanced Solid Malignancies 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Non Small Cell Lung Cancer NSCLC 1 Non - Small Cell Lung Cancer NSCLC 1 Neoplasms 1 Lung Cancer Metastatic 1 Kidney Neoplasms 1 Fallopian Tube Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 EGFR Mutant Advanced Non Small Cell Lung Cancer 1 Disease Progression 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Carcinoma, Renal Cell 1

Interventions

Paclitaxel 2 Carboplatin 2 tremelimumab 1 pembrolizumab 1 necitumumab 1 envafolimab 1 durvalumab 1 Nivolumab 1 Gemcitabine 1 Endostatins 1 Drug Therapy 1 Cisplatin 1 Afatinib 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03319316 2022-01-10

SOLUTION

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡